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Abstract
High rates of interpatient variability in drug metabolism and drug
response for nearly all medications lead to the hypothesis that
assessment of an individual patient's genotype with respect to their
ability to metabolize certain drugs can be a useful tool in predicting a patient's responsiveness to certain medications. Evaluating
patients using pharmacogenomics as a basis for assessment could
allow pharmacists to decide which treatment options would be most
efficacious in a given patient and, thereby, have significant impact
in the clinical setting. This holds true especially in the case of
prodrugs, which require in vivo activation to an active or more active
form. Codeine is a prodrug whose clinical efficacy depends greatly
on its metabolism to more active forms by both cytochrome P450
enzymes and uridine diphosphate glucuronyltransferase enzymes
and is affected by the activity of transporters and the structure of
its target receptor. 4 Evaluation of a patient's metabolic capacity
concerning these enzymes, as well as any "abnormalities" in transporter activity or receptor structure, could indicate if the patient will
receive adequate pain relief from a given dose of codeine.

Introduction
In recent years, the connection between drug metabolism and genetics has been more thoroughly validated thanks to studies on genetic
variability and drug effects. 1 For nearly all medications, interpatient
response variability has been found to be the rule rather than the exception. It is hypothesized that 20-40 percent of differences in patients with
respect to drug response can be described by variations in a patient's
phenotype, the observable traits that result from the genotype, which
can include the patient's ability to metabolize drugs due to the expression of enzymesY These variations are commonly identified through
the discovery of single-nucleotide polymorphisms (SNPs), the most
common genetic variations in human DNA, which occur when one single
base pair replaces another. 3 Through the use of an individual's genetic
background and by paying particular attention to those genes coding
for proteins, such as enzymes, transporters and receptors involved in a
drug's pharmacokinetics and pharmacodynamics, pharmacists and other
health care providers can more thoroughly predict a patient's response
to a specific medication.
A clinically relevant example of this is the metabolism of codeine.
Codeine is a prodrug that requires 0-demethylation by cytochrome P450
(GYP) 2D6 and glucuronidation by uridine diphosphate glucuronyltransferase 287 (UGT287) to form its more active metabolites, morphine and
codeine-6-glucuronide. 4 Codeine efficacy also may be significantly affected by polymorphisms in the transporter as well as the receptor itself.

29

The Pharmacy and Wellness Review

Volume two, Issue two

Codeine Metabolism
The CYP2D6 gene is polymorphic, which results in the metabolism of
morphine being highly variable. 2 A complete lack of GYP2D6 activity is
seen in 6-7 percent of Caucasians. Of the known polymorphisms, alleles
*3-*8 have been classified as nonfunctional, which prevents the formation of functional CYP2D6. Alleles *9, *10 and •41 have been associated
with reduced function, and *1, *2, *35 and *41 can be duplicated, which
would result in a significant increase in the expression of functional
CYP2D6.5 GYP2D6 phenotype is determined by the allelic combinations that an individual patient possesses, as described in Table 1. The
frequency of variant CYP2D6 alleles varies greatly interethnically. In
Extensive Metabolizers (EM), approximately 10 percent of the codeine
dose is converted to morphine. 4 In addition to variations in therapeutic
response, an individual's genetic makeup can be used to determine the
safety of codeine. For example, when compared to EMs CYP2D6, poor
metabolizers (PM) experience less respiratory, psychomotor and pupillary effects, though no significant difference was seen in adverse effects,
such as sedation or dry mouth, between the two phenotypes.
Glucuronidation by UGT2B7 accounts for nearly 80 percent of the
metabolism of a given dose, making it the main route of metabolism
for codeine. As a result of this, the codeine-6-glucuronide metabolite
is found at a much higher concentration in the body than codeine, as
demonstrated by the fact that the area under the curve (AUG) values
of codeine-6-glucuronide are 10-15 times higher than that of codeine.
Although the gene that codes for UGT2B7 also has been found to be
polymorphic, less than 20 allelic variants for this gene have been identified. 5 Unlike the polymorphisms associated with CYP2D6, the functional
significance of UGT2B7 polymorphisms has not been well-defined with
in vitro or in vivo studies. Two significant SNPs with respect to opioid
metabolism are SNP G211 T of the UGT287 enzyme and the SNP
A-842 G, which is associated with the regulatory region of the gene that
encodes UGT287. 6 The nomenclature of SNP G211 T denotes that
guanine is replaced by thymine in the DNA sequence, and SNP A-842
G means that adenine is replaced by guanine. The SNP G211 T causes
a change in the amino acid sequence of the resulting protein at position
71, which changes a lipophilic residue, alanine, in the substrate binding
pocket to a hydrophilic residue, serine. This substitution was studied in
a comparison of two cancer patients, and this allele was shown to be
present in the patient with low morphine sensitivity. The SNP A-842 G
has been associated with increased promoter activity, resulting in higher
levels of UGT2B7 and, thus, increased rates in morphine metabolism.
This increased metabolism can be considered another reason why
patients may fail to experience adequate pain relief from opioids.
Another factor that may contribute to the resistance of certain drugs
is P-glycoprotein (P-gp), an efflux transporter, also known as multidrug resistant P-glycoprotein (MRP1 ). 2 P-gp limits the distribution and
enhances the elimination of many drugs from the body in an effort to
protect against a potentially toxic accumulation of the drug.7 Morphine,
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methadone, loperamide and fentanyl have all been confirmed as P-gp
substrates as well as many endogenous and synthetic opioid peptides. 5
Polymorphisms that increase or decrease the levels of P-gp in membranes can alter drug effects accordingly. 6 Increased expression of P-gp
would result in decreased blood concentrations of these drugs, while
decreased expression would cause the opposite effect. Although P-gp
is highly expressed at many apical epithelium cell membranes, including
in the intestine, which influences drug absorption, its most significant
impact is at capillary endothelial cells of the blood-brain barrier and
blood-cerebrospinal fluid barrier, where it functions to determine CNS
exposure to various substrates. 5

Codeine: A Case Report
Codeine does not produce an adequate analgesic response in 6-7
percent of the Caucasian population because these individuals lack
functional CYP2D6 enzymes. 2 This percentage of the population is
homozygous for non-functional mutant CYP2D6 alleles and, therefore,
is unable to convert codeine to morphine, which provides the pain relief.
In another published case report, a 65-year-old woman was given what
was considered to be standard doses of paracetamol, also known as
acetaminophen, and codeine for the treatment of pain. However, only
minor pain relief was seen, and subsequent increases in the doses were
not found to improve the analgesia and resulted in the patient experiencing undesirable side effects. The patient underwent genetic testing for
CYP2D6 polymorphisms, and it was found that she completely lacked
any functional CYP2D6 enzymes. Consequently, this patient was unable
to get pain relief from codeine because she is part of the small percentage of the Caucasian population with this genetic variation in which
morphine was not formed.

The mu opioid receptor, coded for by the opioid receptor, mu 1 (OPRM1)
gene, is the preferred target of many opioid drugs, especially morphine. 8
There have been more than 100 genetic polymorphisms identified in the
OPRM1 gene. These variations have been noted to produce more than
20 amino acid sequences and have polymorphic frequencies of more
than 1 percent. 5
Morphine: A Case Report
According to guidelines from the World Health Organization (WHO), one
of the leading pharmacological treatments for moderate to severe cancer
pain is oral morphine. 6 However, the analgesic response to morphine
is variable, and both genetic and non-genetic factors contribute to this
unpredictability. Some of these genetic factors include variations in the
genes for the drug's target receptor, drug-metabolizing enzymes and
drug transporters. A published case report describes the treatment of a
55-year-old woman with lung carcinoma and bone metastases who was
given morphine for the treatment of severe pain and did not experience
an adequate analgesic response. Her morphine dose was increased
from 20 mg/day to 75 mg/day, but her pain still was not relieved.
After undergoing genetic testing for several polymorphisms, this patient
was classified as a poor responder to morphine due to the detection of
several SNPs.6 One of the SNPs identified was a genetic variation in the
mu-opioid receptor (MOR-1 ). The patient was found to be heterozygous
for the MOR-1 polymorphism A118 G, a genotype that typically results
in patients needing an 18 percent higher dose of morphine compared
to patients with the wildtype genotype. In addition, the patient had a
genetic variation involving the UGT2B7, which altered the production
of normal metabolites of morphine, one of which is active at opioid
receptors and one that is inactive. This patient was homozygous for the
UGT2B7 promoter polymorphism A-842 G, which causes an increase
in promoter activity, therefore resulting in higher levels of the enzyme.
With more of the UGT2B7 enzyme present, the patient experienced an
increased rate of morphine metabolism, which contributed to her poor
analgesic response. Lastly, the patient also had a SNP in the gene for
P-gp, which is involved in the distribution of morphine. The patient was
heterozygous for the polymorphism C3435 T, which increases the stability of the mRNA transcript and results in an expression of higher levels
of the transporter. Consequently, the patient was less able to absorb and
distribute morphine to various regions of the body, including the central
nervous system. The overall end result of the patient having all three of
these genetic polymorphisms was that she could not get adequate pain
relief from morphine.

Phannacogenomlcs

Conclusion
These case reports illustrate that there is a need to consider genetic
factors when prescribing an opioid for analgesia because of the number
of genetic polymorphisms in various enzymes, receptors and transporters that can significantly alter the response to this class of medications. 6
For instance, being able to use genetic tests to identify a patient as
a poor responder to morphine would allow an alternative opioid to be
chosen as the first-line treatment, thereby minimizing the incidence and
extent of pain experienced by the patient for the duration of therapy.
If point-of-care genetic testing could be done to identify patients who
lack functional CYP2D6 enzymes, these patients could be prescribed
an alternative drug instead of codeine, which would ultimately spare
the patient from experiencing inadequate pain relief as a result of their
inability to convert codeine to morphine. In the future, the use of genetic
screenings prior to prescribing and dispensing opioids may allow health
care providers to prevent this type of insufficient drug therapy; however,
further advancements are needed in this area in order for it to have a
more significant role in clinical practice. As pharmacists, we can improve
patient care by providing different analgesic options to patients whose
pain is not adequately controlled by opioids. These opioid resistant patients could be affected by one or more genetic factors, including having
a polymorphism in either a CYP450 or UGT enzyme. Pharmacists can
be the health care provider to counsel patients on this issue and provide
them with other options, such as finding another pain medication that
is metabolized by different CYP450 enzymes or by proposing another
route of delivery for their current medication. For example, using a
transdermal or buccal delivery route for a medication will avoid extensive
first-pass metabolism by the liver, allowing more drug to be available
for the patient. This simple change can make a substantial difference
in a patient's therapy by helping to alleviate more of the patient's pain.
Although this area of pharmacotherapy is still in the beginning stages
of development, pharmacists have the opportunity to use pharmacogenomic methods to help improve patient care and enhance the outcome
of a patient's opioid drug therapy.
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Table 1. Phenotypic Designations for CYP2D6 Expression5
Genotype

Phenotypic Designation

Two nonfunctional alleles
At least one reduced function allele

Poor metabolizer (PM)
Intermediate metabolizer (IM)

At least one functional allele

Extensive metabolizer (EM)

Multiple copies of a functional allele Ultrarapid metabolizer (UM)
and/or an allele with a mutation in the
promoter region
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